CClinicalTrials.gg
Active, not recruitingNCT06842784Updated Jul 30, 2026

Impact of Extreme Heat on Myocardial Blood Flow and Flow Reserve in Young and Older Adults

An observational study in Aging, Heat Stress and Hyperthermia, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by University of Texas Southwestern Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
All
01

Study summary

Extreme heat causes a disproportionate number of hospitalizations and deaths in older adults relative to any other age group. Importantly, many hospitalizations and deaths are primarily due to cardiovascular events such as myocardial infarction. Previous data indicate that older adults have attenuated skin blood flow and sweating responses when exposed to heat, resulting greater increase in core body temperature. Despite these observations, relatively little is known about the risk for myocardial ischemia potentially contributing to the aforementioned higher morbidity and mortality in older adults during heat waves. The broad objective of this work is to determine the impact of ambient heat exposure on myocardial blood flow and flow reserve in young and older adults. Aim 1 will test the hypothesis that older adults exhibit attenuated myocardial flow reserve compared to young adults during heat stress. Aim 2 will determine if the percent of maximal myocardial flow reserve (assess via vasodilator stress) during heat exposure is higher in older adults compared to young adults. The expected outcome from this body of work will improve our understanding of the consequences of aging on cardiovascular responses to ambient heat stress.

02

Conditions studied

  • Aging
  • Heat Stress
  • Hyperthermia
  • Heat Strain
03

In context

Heat Stress Disorders

111 studies on the registry are indexed under Heat Stress Disorders; 45 are open to participants now.

This study's planned enrollment of 24 is below the median of 55 across 13 observational studies indexed under Heat Stress Disorders.

Browse Heat Stress Disorders studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 990 studies on the registry; 201 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 101 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be healthy younger and older individuals identified from the general population.

Inclusion criteria

  • Healthy male and female individuals
  • 18-35 years or 65+ years of age
  • Free of any underlying moderate to serious medical conditions

Exclusion criteria

Exclusion Criteria:

  • Known heart disease; other chronic medical conditions requiring regular medical therapy including cancer, diabetes, neurological diseases, uncontrolled hypertension, and uncontrolled hypercholesterolemia.
  • Taking of any medications (such as beta blockers and non-dihydropyridine calcium channel blockers) that have known influences on either cardiac function or sweating responses.
  • Abnormalities detected on routine screening.
  • Current smokers, as well as individuals who regularly smoked within the past 3 years.
  • Body mass index of greater than 30 kg/m\^2
  • Pregnant individuals
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
24 participants (estimated)
Patient registry
No

Groups and cohorts

  • Young participants

    Individuals aged 18-39 years

    Other: Ambient heat stress

  • Older participants

    Individuals aged 65 years or older

    Other: Ambient heat stress

Interventions

  • OtherAmbient heat stress

    3-hour ambient heating in 44°C and 20% relative humidity

06

What researchers measure

Primary outcomes

  1. Myocardial flow reserve

    Measured via myocardial contrast echocardiography.

    Time frame: The difference in the change from baseline to a vasodilator stress test and the change from baseline to after 3-hours of heat stress.

  2. Myocardial blood flow

    Measured via myocardial contrast echocardiography.

    Time frame: The change from baseline to after 3 hours of heat stress.

Secondary outcomes

  1. Core temperature

    Measured via ingestible telemetric pill.

    Time frame: The change from baseline to after 3 hours of heat stress..

  2. Indices of left and right ventricular function

    Measured via echocardiography.

    Time frame: At baseline and after 3 hours of heat stress.

  3. Heart rate

    Measured via electrocardiogram.

    Time frame: At baseline, during exercise- after 20 minutes and 2 hours in the heat, and at rest after 3 hours of heat stress.

  4. Blood pressure

    Measured via automated auscultation of the brachial artery.

    Time frame: At baseline, during exercise- after 20 minutes and 2 hours in the heat, and at rest after 3 hours of heat stress.

07

Study locations

1 site
  • Texas Health Presbyterian Hospital Dallas
    Dallas, Texas 75231, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06842784
Lead sponsor
University of Texas Southwestern Medical Center
Collaborators
National Institute on Aging (NIA), The Cleveland Clinic
Responsible party
James MacNamara (Assistant Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Feb 24, 2025
Start date
Feb 3, 2025
Primary completion
Apr 30, 2026
Completion
Feb 1, 2027 (estimated)
Last update
Jul 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion